Posted inClinical Updates Neurology
Azetukalner Shows Promising Efficacy and Safety in Adults with Drug-Resistant Focal Seizures: Insights from the Phase 3 X-TOLE2 Trial
The X-TOLE2 phase 3 trial demonstrates that azetukalner significantly reduces focal seizure frequency with favorable safety, offering a novel option for adults with drug-resistant epilepsy.
